See more : WashTec AG (WSU.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Inozyme Pharma, Inc. (INZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inozyme Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- More Acquisitions Plc (TMOR.L) Income Statement Analysis – Financial Results
- Activation Group Holdings Limited (9919.HK) Income Statement Analysis – Financial Results
- Arr Planner Co., Ltd. (2983.T) Income Statement Analysis – Financial Results
- Nichidai Corporation (6467.T) Income Statement Analysis – Financial Results
- The Motor & General Finance Limited (MOTOGENFIN.NS) Income Statement Analysis – Financial Results
Inozyme Pharma, Inc. (INZY)
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.29M | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| Gross Profit | -1.29M | -1.18M | -1.05M | -217.00K | -83.00K | -26.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.85M | 47.85M | 37.72M | 46.49M | 16.22M | 8.10M |
| General & Administrative | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Other Expenses | 0.00 | -319.00K | -189.00K | 247.00K | -24.00K | 4.35M |
| Operating Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Cost & Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Interest Income | 7.84M | 1.93M | 211.00K | 370.00K | 1.11M | 284.00K |
| Interest Expense | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 833.00K | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| EBITDA | -74.81M | -65.88M | -55.97M | -56.82M | -20.72M | -11.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -75.65M | -68.68M | -56.65M | -57.04M | -20.81M | -11.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.48M | 1.61M | 22.00K | 617.00K | 1.08M | 4.63M |
| Income Before Tax | -71.17M | -67.06M | -56.62M | -56.42M | -19.72M | -6.96M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.61M | -211.00K | -587.00K | -1.11M | 4.63M |
| Net Income | -71.17M | -65.45M | -56.41M | -55.84M | -18.62M | -6.96M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| EPS Diluted | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| Weighted Avg Shares Out | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
| Weighted Avg Shares Out (Dil) | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that Gayle Gironda has been appointed as senior vice president of human...
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency
- Clinical trial initiation expected in mid-2021 – - Preliminary safety and biomarker data expected by the end of 2021 -
Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights
– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 –
Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today announced that preclinical data from a study examining INZ-701 for the potential...
Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
- Study results underscore high and shifting disease impacts across age groups, reflecting evolution of disease symptomology - - Study results underscore high and shifting disease impacts across age groups, reflecting evolution of disease symptomology -
Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced that data from the burden of illness in infantile onset...
Inozyme Pharma Expands its Scientific Advisory Board
- Appoints veteran leaders with deep scientific and clinical expertise in vascular calcification, renal disease, and diseases with neointimal proliferation - - Appoints veteran leaders with deep scientific and clinical expertise in vascular calcification, renal disease, and diseases with neointimal...
Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights
– Received Orphan Drug Designation by the U.S. Food and Drug Administration for INZ-701 for treatment of ABCC6 deficiency –
Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today announced the appointment of...
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
Source: https://incomestatements.info
Category: Stock Reports